|
DE69820614T2
(de)
*
|
1997-05-30 |
2004-09-30 |
Celltech Therapeutics Ltd., Slough |
Entzündungshemmende tyrosin-derivate
|
|
US6482849B1
(en)
|
1997-06-23 |
2002-11-19 |
Tanabe Seiyaku Co., Ltd. |
Inhibitors of α4β1 mediated cell adhesion
|
|
US6939855B2
(en)
|
1997-07-31 |
2005-09-06 |
Elan Pharmaceuticals, Inc. |
Anti-inflammatory compositions and method
|
|
US6492421B1
(en)
|
1997-07-31 |
2002-12-10 |
Athena Neurosciences, Inc. |
Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6583139B1
(en)
|
1997-07-31 |
2003-06-24 |
Eugene D. Thorsett |
Compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6489300B1
(en)
|
1997-07-31 |
2002-12-03 |
Eugene D. Thorsett |
Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6423688B1
(en)
|
1997-07-31 |
2002-07-23 |
Athena Neurosciences, Inc. |
Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6291453B1
(en)
|
1997-07-31 |
2001-09-18 |
Athena Neurosciences, Inc. |
4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6362341B1
(en)
|
1997-07-31 |
2002-03-26 |
Athena Neurosciences, Inc. |
Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US7030114B1
(en)
|
1997-07-31 |
2006-04-18 |
Elan Pharmaceuticals, Inc. |
Compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6559127B1
(en)
|
1997-07-31 |
2003-05-06 |
Athena Neurosciences, Inc. |
Compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6645939B1
(en)
|
1997-11-24 |
2003-11-11 |
Merck & Co., Inc. |
Substituted β-alanine derivatives as cell adhesion inhibitors
|
|
MY153569A
(en)
|
1998-01-20 |
2015-02-27 |
Mitsubishi Tanabe Pharma Corp |
Inhibitors of ?4 mediated cell adhesion
|
|
US6329372B1
(en)
|
1998-01-27 |
2001-12-11 |
Celltech Therapeutics Limited |
Phenylalanine derivatives
|
|
DE69919334T2
(de)
|
1998-02-26 |
2005-08-04 |
Celltech Therapeutics Ltd., Slough |
Phenylalaninderivate als inhibitoren von alpha4 integrinen
|
|
US6521626B1
(en)
|
1998-03-24 |
2003-02-18 |
Celltech R&D Limited |
Thiocarboxamide derivatives
|
|
GB9811159D0
(en)
|
1998-05-22 |
1998-07-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9811969D0
(en)
|
1998-06-03 |
1998-07-29 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6685617B1
(en)
|
1998-06-23 |
2004-02-03 |
Pharmacia & Upjohn Company |
Inhibitors of α4β1 mediated cell adhesion
|
|
GB9814414D0
(en)
|
1998-07-03 |
1998-09-02 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9821061D0
(en)
|
1998-09-28 |
1998-11-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9821222D0
(en)
|
1998-09-30 |
1998-11-25 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9825652D0
(en)
|
1998-11-23 |
1999-01-13 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9826174D0
(en)
|
1998-11-30 |
1999-01-20 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9828074D0
(en)
*
|
1998-12-18 |
1999-02-17 |
Glaxo Group Ltd |
Therapeutically useful compounds
|
|
US6486193B2
(en)
|
1998-12-31 |
2002-11-26 |
Aventis Pharmaceuticals Inc. |
3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
|
|
EP1150951A1
(en)
*
|
1998-12-31 |
2001-11-07 |
Aventis Pharmaceuticals Inc. |
3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
|
|
AU769741B2
(en)
|
1999-01-22 |
2004-02-05 |
Elan Pharmaceuticals, Inc. |
Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
ATE377003T1
(de)
|
1999-01-22 |
2007-11-15 |
Elan Pharm Inc |
Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
|
|
EP1150997A1
(en)
*
|
1999-01-25 |
2001-11-07 |
Elan Pharmaceuticals, Inc. |
Compounds which inhibit leukocyte adhesion mediated by vla-4
|
|
US6436904B1
(en)
|
1999-01-25 |
2002-08-20 |
Elan Pharmaceuticals, Inc. |
Compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6407066B1
(en)
|
1999-01-26 |
2002-06-18 |
Elan Pharmaceuticals, Inc. |
Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6518283B1
(en)
|
1999-05-28 |
2003-02-11 |
Celltech R&D Limited |
Squaric acid derivatives
|
|
US6756378B2
(en)
|
1999-06-30 |
2004-06-29 |
Pharmacopeia Drug Discovery, Inc. |
VLA-4 inhibitor compounds
|
|
GB2354440A
(en)
*
|
1999-07-20 |
2001-03-28 |
Merck & Co Inc |
Aryl amides as cell adhesion inhibitors
|
|
JP2003506491A
(ja)
|
1999-08-13 |
2003-02-18 |
バイオジェン インコーポレイテッド |
細胞接着インヒビター
|
|
US6534513B1
(en)
|
1999-09-29 |
2003-03-18 |
Celltech R&D Limited |
Phenylalkanoic acid derivatives
|
|
DK1244625T3
(da)
*
|
1999-12-06 |
2005-10-10 |
Hoffmann La Roche |
4-pyridinyl-n-acyl-l-phenylalaniner
|
|
US6388084B1
(en)
|
1999-12-06 |
2002-05-14 |
Hoffmann-La Roche Inc. |
4-pyridinyl-n-acyl-l-phenylalanines
|
|
EP1237878B1
(en)
*
|
1999-12-06 |
2007-03-21 |
F. Hoffmann-La Roche Ag |
4-pyrimidinyl-n-acyl-l-phenylalanines
|
|
US6380387B1
(en)
|
1999-12-06 |
2002-04-30 |
Hoffmann-La Roche Inc. |
4-Pyrimidinyl-n-acyl-l phenylalanines
|
|
US6455539B2
(en)
|
1999-12-23 |
2002-09-24 |
Celltech R&D Limited |
Squaric acid derivates
|
|
DE19962936A1
(de)
|
1999-12-24 |
2001-06-28 |
Bayer Ag |
Neue beta-Aminosäureverbindungen als Integrinantagonisten
|
|
EE200200372A
(et)
|
1999-12-28 |
2003-12-15 |
Pfizer Products Inc. |
VLA-4 sõltuva raku seostumise mittepeptiidsed inhibiitorid, mis on kasutatavad põletiku-, autoimmuun- ja respiratoorsete haiguste raviks
|
|
ATE375330T1
(de)
|
2000-04-17 |
2007-10-15 |
Ucb Pharma Sa |
Enamin-derivate als zell-adhäsionsmoleküle
|
|
US6403608B1
(en)
|
2000-05-30 |
2002-06-11 |
Celltech R&D, Ltd. |
3-Substituted isoquinolin-1-yl derivatives
|
|
US6545013B2
(en)
|
2000-05-30 |
2003-04-08 |
Celltech R&D Limited |
2,7-naphthyridine derivatives
|
|
US6960597B2
(en)
*
|
2000-06-30 |
2005-11-01 |
Orth-Mcneil Pharmaceutical, Inc. |
Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
|
|
AU2001267753A1
(en)
|
2000-07-07 |
2002-01-21 |
Celltech R And D Limited |
Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
|
|
EP1305291A1
(en)
|
2000-08-02 |
2003-05-02 |
Celltech R&D Limited |
3-substituted isoquinolin-1-yl derivatives
|
|
MY129000A
(en)
|
2000-08-31 |
2007-03-30 |
Tanabe Seiyaku Co |
INHIBITORS OF a4 MEDIATED CELL ADHESION
|
|
IL154993A0
(en)
*
|
2000-09-29 |
2003-10-31 |
Neurogen Corp |
High affinity small molecule c5a receptor modulators
|
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
|
EP3674322A1
(en)
|
2002-02-25 |
2020-07-01 |
Biogen MA Inc. |
Administration of agents for the treatment of inflammation
|
|
TWI281470B
(en)
|
2002-05-24 |
2007-05-21 |
Elan Pharm Inc |
Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
|
|
TW200307671A
(en)
|
2002-05-24 |
2003-12-16 |
Elan Pharm Inc |
Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
|
|
JP2005535710A
(ja)
|
2002-08-09 |
2005-11-24 |
トランス テック ファーマ，インコーポレイテッド |
アリールおよびヘテロアリール化合物ならびに凝固を調節する方法
|
|
JP2006511500A
(ja)
|
2002-10-30 |
2006-04-06 |
メルク エンド カムパニー インコーポレーテッド |
γ−アミノアミド系のケモカイン受容体活性調節剤
|
|
JP2006516624A
(ja)
|
2003-01-24 |
2006-07-06 |
エラン ファーマシューティカルズ，インコーポレイテッド |
脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
|
|
US7208601B2
(en)
|
2003-08-08 |
2007-04-24 |
Mjalli Adnan M M |
Aryl and heteroaryl compounds, compositions, and methods of use
|
|
WO2005014532A1
(en)
|
2003-08-08 |
2005-02-17 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions and methods of use
|
|
JP2007501844A
(ja)
|
2003-08-08 |
2007-02-01 |
トランス テック ファーマ，インコーポレイテッド |
アリール及びヘテロアリール化合物、組成物並びに使用方法
|
|
CA2562235C
(en)
|
2004-04-13 |
2013-09-24 |
Incyte Corporation |
Piperazinylpiperidine derivatives as chemokine receptor antagonists
|
|
FR2869904B1
(fr)
*
|
2004-05-07 |
2006-07-28 |
Fournier S A Sa Lab |
Modulateurs des recepteurs lxr
|
|
BRPI0513143A
(pt)
|
2004-07-08 |
2008-04-29 |
Elan Pharm Inc |
antagonistas de vla-4 multivalentes compreendendo porções poliméricas
|
|
US7196112B2
(en)
|
2004-07-16 |
2007-03-27 |
Biogen Idec Ma Inc. |
Cell adhesion inhibitors
|
|
WO2007041270A1
(en)
|
2005-09-29 |
2007-04-12 |
Elan Pharmaceuticals, Inc. |
Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
|
|
CA2851103A1
(en)
|
2005-09-29 |
2007-04-12 |
Elan Pharmaceuticals, Inc. |
Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
|
|
MEP1008A
(xx)
|
2005-12-21 |
2010-02-10 |
Incyte Corp |
3-aminociklopentankarboksamidi kao modulatori receptora hemokina
|
|
CN101389611B
(zh)
|
2006-02-27 |
2012-07-18 |
伊兰制药公司 |
抑制由vla-4所介导的白血球粘附的嘧啶磺酰胺化合物
|
|
TW200811164A
(en)
*
|
2006-05-12 |
2008-03-01 |
Jerini Ag |
New heterocyclic compounds for the inhibition of integrins and use thereof
|
|
US20100150915A1
(en)
|
2007-02-20 |
2010-06-17 |
Stewart Edward J |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
|
EA022201B1
(ru)
|
2008-04-11 |
2015-11-30 |
Мерримак Фармасьютикалз, Инк. |
Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
|
|
GEP20146064B
(en)
|
2008-11-26 |
2014-03-25 |
Pfizer |
3-minocyclopentanecarboxamides as chemokine receptor modulators
|
|
WO2010090764A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
JP5420761B2
(ja)
|
2009-05-28 |
2014-02-19 |
ノバルティス アーゲー |
ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
|
|
EA201101672A1
(ru)
|
2009-05-28 |
2012-06-29 |
Новартис Аг |
Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
|
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
|
EP2956464B1
(en)
|
2013-02-14 |
2018-03-28 |
Novartis AG |
Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
|
|
KR20150119107A
(ko)
|
2013-02-14 |
2015-10-23 |
노파르티스 아게 |
개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체
|
|
WO2015136468A1
(en)
|
2014-03-13 |
2015-09-17 |
Prothena Biosciences Limited |
Combination treatment for multiple sclerosis
|
|
WO2018085578A1
(en)
*
|
2016-11-02 |
2018-05-11 |
Saint Louis University |
Integrin inhibitors in combination with an agent which interacts with a chemokine receptor
|
|
US20220119383A1
(en)
|
2018-10-30 |
2022-04-21 |
Gilead Sciences, Inc. |
Quinoline derivatives as alpha4beta7 integrin inhibitors
|
|
KR102641718B1
(ko)
|
2018-10-30 |
2024-02-29 |
길리애드 사이언시즈, 인코포레이티드 |
알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
|
|
KR102659859B1
(ko)
|
2018-10-30 |
2024-04-25 |
길리애드 사이언시즈, 인코포레이티드 |
알파4β7 인테그린의 억제를 위한 화합물
|
|
CN112996786B
(zh)
|
2018-10-30 |
2024-08-20 |
吉利德科学公司 |
用于抑制α4β7整合素的化合物
|
|
CN119431230A
(zh)
|
2019-08-14 |
2025-02-14 |
吉利德科学公司 |
用于抑制α4β7整合素的化合物
|
|
PH12022553378A1
(en)
|
2020-06-10 |
2024-03-25 |
Univ Leuven Kath |
Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
|
|
EP4366831A4
(en)
|
2021-07-09 |
2025-06-11 |
Aligos Therapeutics, Inc. |
ANTI-VIRAL COMPOUNDS
|
|
US12065428B2
(en)
|
2021-09-17 |
2024-08-20 |
Aligos Therapeutics, Inc. |
Anti-viral compounds
|